Members interested in new imaging modalities for prostate cancer
At numerous APC champs and navigator meetings, members have been sharing their interest in accessing new imaging modalities for their patients. APC physicians and navigators often detect changes in a patient’s disease based on PSA, ALP or symptoms before changes are detected on traditional bone scans. In both the biochemical-recurrent and castrate-resistant space, these changes are often associated with patient anxiety as intervention is usually withheld until new sites of disease are located. One such new modality is the Axumin® (fluciclovine F 18) injection for positron emission tomography (PET) imaging. Many members have inquired about where to access this technology for their patients. See below for a list of sites, as well as a brief clinical overview from UroToday.
Augmenix® announces Medicare reimbursement rates for SpaceOAR® Hydrogel
SpaceOAR is the first and only “spacing” device to protect the rectum during radiation treatment of prostate tumors. The new Medicare Reimbursement Rates for CPT Code 55874 will be effective January 2018.
Bladder research highlighted at annual Society of Urologic Oncology (SUO) meeting
Numerous trials are researching immunotherapy in bladder cancer. While most current drug approvals are in the 2L or 1L for platinum ineligible patients (pembrolizumab, atezolizumab), exciting work is being done in the adjuvant and BCG-refractory setting. We look forward to more advancements in this space to benefit patients in the urology setting.